Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
Explore this paper's citation graph
Summary
It is found that drug-resistant cancers still recruit ER to the chromatin, but that ER binding is a dynamic process, with the acquisition of unique ER-binding regions in tumours from patients that are likely to relapse.
- Type
- article
- Published
- 2012-01-04
- Cited by
- 2,009
- References
- 32
- Access
- Open access
- OpenAlex
- https://openalex.org/W2155826575
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:4381811
Keywords
FOXA1, Transcription factor, Breast cancer, Tamoxifen, Cancer research
References
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
- An Oestrogen Receptor α-bound Human Chromatin Interactome
- Semi-Supervised Methods to Predict Patient Survival from Gene Expression Data
- Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.
- Quantitative transcriptional control of ErbB receptor signaling undergoes graded to biphasic response for cell differentiation.
- ChIP-seq: using high-throughput sequencing to discover protein-DNA interactions
- A gene-expression signature to predict survival in breast cancer across independent data sets
- Isolation of pure populations of epithelial and myoepithelial cells from the normal human mammary gland using immunomagnetic separation with Dynabeads.
- The humoral immune system has a key prognostic impact in node-negative breast cancer.
- microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer.
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression data
- Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
- ChIP‐Seq of ERα and RNA polymerase II defines genes differentially responding to ligands
- Classifying the estrogen receptor status of breast cancers by expression profiles reveals a poor prognosis subpopulation exhibiting high expression of the ERBB2 receptor.
- Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance.
- MoD Tools: regulatory motif discovery in nucleotide sequences from co-regulated or homologous genes
- Whole-Genome Cartography of Estrogen Receptor α Binding Sites
- Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.
- Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1.
- A gene-expression signature as a predictor of survival in breast cancer.
Cited by
- Genetics of Multiple Sclerosis
- Detecting DNA-protein interactions in living cells--ChIP approach.
- Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures
- Epithelial cancers in the post-genomic era: should we reconsider our lifestyle?
- Altered histone modifications in cancer.
- DOT1L-mediated H3K79me2 modification critically regulates gene expression during cardiomyocyte differentiation
- Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance.
- GalNAc-T4 putatively modulates the estrogen regulatory network through FOXA1 glycosylation in human breast cancer cells
- BRD4 localization to lineage-specific enhancers is associated with a distinct transcription factor repertoire
- upSET, the Drosophila homologue of SET3, Is Required for Viability and the Proper Balance of Active and Repressive Chromatin Marks
- Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner
- Interaction of WBP2 with ERα increases doxorubicin resistance of breast cancer cells by modulating MDR1 transcription
- Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers
- Universal NicE-seq for high-resolution accessible chromatin profiling for formaldehyde-fixed and FFPE tissues
- Modulation of estrogen receptor alpha activity and expression during breast cancer progression.
- MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling
- Serine protease NAL1 exerts pleiotropic functions through degradation of TOPLESS-related corepressor in rice
- An investigation in to the role of fatty acid binding protein-7, insulin like growth factor binding protein-2 and phosphatase and tensin homolog in triple negative breast cancer, in vitro and in vivo
- FOXP1 and estrogen signaling in breast cancer.
- Tipping the Balance: Factors That Influence the ER Signaling Network in Breast Cancer
Related papers
- Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer
- FOXA1 expression in Iraqi women with ER+ breast cancer: A case control study
- FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer
- FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer
- FOXA1 is a critical determinant of Estrogen Receptor function and endocrine response
- FOXA1 defines cancer cell specificity
- 5 INVITED Biological roles of PI 3-kinase isoforms
- miR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer.
- Mechanisms of in vivo binding site selection of the hematopoietic master transcription factor PU.1
- Synergistic activation of the Atlantic salmon hepatocyte nuclear factor (HNF) 1 promoter by the orphan nuclear receptors HNF4 and chicken ovalbumin upstream promoter transcription factor I (COUP-TFI).